

Laura Mezquita

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7629805/laura-mezquita-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92
papers

5,238
citations

23
h-index

72
g-index

114
ext. papers

7,446
ext. citations

4.8
avg, IF

5.33
L-index

#	Paper	IF	Citations
92	Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. <i>Science</i> , 2018 , 359, 91-97	33.3	2203
91	Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2872-2878	2.2	477
90	Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. <i>JAMA Oncology</i> , 2018 , 4, 1543-1552	13.4	380
89	Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. <i>Annals of Oncology</i> , 2019 , 30, 1321-1328	10.3	365
88	Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018 , 4, 351-357	13.4	357
87	Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. <i>European Journal of Cancer</i> , 2018 , 88, 38-47	7.5	178
86	Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1244-1254	8.9	106
85	Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?. <i>Cancer Treatment Reviews</i> , 2017 , 60, 60-68	14.4	83
84	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 914-947	8.9	71
83	Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 1147-1157	8.8	58
82	Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 102-102	2.2	56
81	Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 242-255	12.9	55
80	Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in -Rearranged Non-Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 6671-6682	12.9	48
79	Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020 , 6, 1039-1046	13.4	36
78	Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2018 , 10, S1516-S1533	2.6	36
77	Progress in the Management of Advanced Thoracic Malignancies in 2017. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 301-322	8.9	34
76	Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9010-9010	2.2	33

75	Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. <i>Clinical Cancer Research</i> , 2021 , 27, 492-503	12.9	31
74	Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 383-391	8.9	30
73	Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 148, 102906	7	24
72	Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019 , 116, 182-189	7.5	23
71	Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF non-small cell lung cancer. <i>European Journal of Cancer</i> , 2020 , 132, 211-223	7.5	23
70	Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing. <i>Frontiers in Immunology</i> , 2019 , 10, 1505	8.4	23
69	Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients. <i>European Journal of Cancer</i> , 2019 , 108, 88-96	7.5	22
68	Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies. <i>European Journal of Cancer</i> , 2020 , 129, 71-79	7.5	21
67	Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab. <i>Cancers</i> , 2020 , 12,	6.6	20
66	C797S, T790M and sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR. <i>Oncotarget</i> , 2018 , 9, 37393-37406	3.3	19
65	CD103CD8 T Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17. <i>Cell Reports Medicine</i> , 2020 , 1, 100127	18	18
64	Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting and Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	18
63	The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 64, 162-174	14	17
62	Safety of osimertinib in EGFR-mutated non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 1239-1248	4.1	17
61	Durvalumab for the treatment of non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2018 , 12, 627-639	3.8	16
60	Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1400-1407	8.9	16
59	Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2020 , 21, e497-e510	4.9	15
58	Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2020 , 122, 340-347	8.7	15

57	Executive summary of the SEPAR recommendations for the diagnosis and treatment of non-small cell lung cancer. <i>Archivos De Bronconeumologia</i> , 2016 , 52, 378-88	0.7	15
56	Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer. <i>PLoS ONE</i> , 2018 , 13, e0204490	3.7	15
55	Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI). <i>Cancers</i> , 2020 , 12,	6.6	14
54	Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer. <i>Cancers</i> , 2020 , 12,	6.6	14
53	Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy. <i>European Journal of Cancer</i> , 2021 , 145, 221-229	7.5	14
52	Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	13
51	High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1232-1239	8.9	12
50	Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2019 , 13, 1753466619885530	4.9	12
49	Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9003-9003	2.2	12
48	Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay. <i>PLoS ONE</i> , 2020 , 15, e0234302	3.7	11
47	The role of brigatinib in crizotinib-resistant non-small cell lung cancer. <i>Cancer Management and Research</i> , 2018 , 10, 123-130	3.6	11
46	Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with -Mutant Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 6242-6253	12.9	10
45	Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?.. <i>Immunotherapy</i> , 2019 , 11, 1149-1160	3.8	8
44	Prolonged Leptomeningeal Responses with Brigatinib in Two Heavily Pretreated ALK-Rearranged Non-Small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e215-e217	8.9	7
43	Effect of tumor growth rate (TGR) on response patterns of checkpoint inhibitors in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9034-9034	2.2	7
42	Fast-progression (FP), hyper-progression (HPD) and early deaths (ED) in advanced non-small cell lung cancer (NSCLC) patients (pts) upon PD-(L)-1 blockade (IO).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9107-9107	2.2	7
41	Durvalumab in non-small-cell lung cancer patients: current developments. <i>Future Oncology</i> , 2018 , 14, 205-222	3.6	7
40	Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. <i>European Journal of Cancer</i> , 2021 , 151, 211-220	7.5	6

39	Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma. <i>European Radiology</i> , 2020 , 30, 5021-5028	8	6
38	Integrin-Mediated activation of TGF- β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade. <i>Nature Communications</i> , 2021 , 12, 5209	17.4	6
37	Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy.. <i>JCO Precision Oncology</i> , 2020 , 4, 829-840	3.6	5
36	Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. <i>Npj Precision Oncology</i> , 2021 , 5, 67	9.8	5
35	Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100023	1.4	4
34	Hepatic Intra-Arterial Chemotherapy With Immunotherapy in NSCLC. <i>Journal of Thoracic Oncology</i> , 2019 , 14, e215-e216	8.9	4
33	Letter to the Editor about Sorich et al. <i>Journal of Thoracic Oncology</i> , 2019 , 14, e209	8.9	4
32	Spontaneous tumor lysis syndrome in the setting of small cell lung cancer: Report of two cases and review of the literature. <i>Cancer Treatment and Research Communications</i> , 2016 , 9, 92-95	2	4
31	Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy. <i>Lung Cancer</i> , 2021 , 159, 45-55	5.9	4
30	Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2019 , 20, 305-312.e3	4.9	3
29	Acrometastasis as the initial presentation of lung adenocarcinoma in a young woman. <i>Archivos De Bronconeumologia</i> , 2016 , 52, 482-3	0.7	3
28	Analysis of single circulating tumor cells (CTCs) to identify resistance mutations to ALK-inhibitors in both ALK-gene and bypass oncogenic pathways.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12038-12038	2.2	3
27	Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. <i>Npj Precision Oncology</i> , 2020 , 4, 27	9.8	3
26	Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer. <i>Cancers</i> , 2020 , 12,	6.6	3
25	Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study. <i>Lung Cancer</i> , 2021 , 155, 114-119	5.9	3
24	Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAF-Mutant Metastatic Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021 , 22, e54-e56	4.9	3
23	The Role of Violent Video Game Exposure, Personality, and Deviant Peers in Aggressive Behaviors Among Adolescents: A Two-Wave Longitudinal Study. <i>Cyberpsychology, Behavior, and Social Networking</i> , 2021 , 24, 32-40	4.4	3
22	Focus on Recommendations for the Management of Non-small Cell Lung Cancer. <i>CardioVascular and Interventional Radiology</i> , 2019 , 42, 1230-1239	2.7	2

21	Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , 2017 , 112, 10-15	5.9	2
20	CD8PD-1 to CD4PD-1 ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers. 2022 , 10,		2
19	Predicting outcomes of advanced non-small cell lung cancer patients treated with PD-1/PDL-1 inhibitors: Independent international validation of the iSEND model.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3015-3015	2.2	2
18	Neutrophil-lymphocyte-ratio to complement the prediction ability of PD-L1 expression for outcomes in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e15102-e15102	2.2	2
17	Association of the Lung Immune Prognostic Index with outcome in patients with metastatic urothelial cancer treated with immune checkpoint inhibitor.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 545-545	2.2	2
16	Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors. <i>Case Reports in Oncological Medicine</i> , 2021 , 2021, 6631859	0.9	2
15	Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer.. <i>Npj Precision Oncology</i> , 2021 , 5, 102	9.8	2
14	Nivolumab-induced pneumonitis complicated by cyst formation. <i>Lung Cancer</i> , 2018 , 122, 258-259	5.9	1
13	How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).. <i>Cancer Treatment Reviews</i> , 2021 , 103, 102335	14.4	1
12	An amplicon-based liquid biopsy for detecting ALK and ROS1 fusions and resistance mutations in advanced non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9095-9095	2.2	1
11	Validation of the lung immune prognostic index (LIPI) in patients with metastatic renal cell carcinoma treated with nivolumab in the GETUG-AFU 26 NIVOREN trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 735-735	2.2	1
10	Clinical efficacy, predictive biomarkers and response patterns of immunotherapy combinations for patients with cancer. <i>Future Oncology</i> , 2020 , 16, 1659-1664	3.6	1
9	Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy. <i>Respiratory Medicine and Research</i> , 2020 , 78, 100788	1.4	1
8	Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. 2021, , 1176. <i>Cancers</i> , 2021 , 13,	6.6	1
7	Development of Thyroid Carcinoma During Treatment With Pembrolizumab in a Lung Cancer Patient. <i>Annals of Thoracic Surgery</i> , 2020 , 109, e397-e399	2.7	0
6	Vaccine Therapy in Non-Small Cell Lung Cancer. <i>Vaccines</i> , 2022 , 10, 740	5.3	0
5	Unusual progressive neurological syndrome in epidermal growth factor receptor-mutated lung adenocarcinoma, diagnosed at autopsy as invasive meningeal carcinomatosis. <i>Archivos De Bronconeumologia</i> , 2016 , 52, 571-572	0.7	
4	Pseudoprogression in a Patient with Metastatic Lung Adenocarcinoma Treated with Nivolumab. <i>Archivos De Bronconeumologia</i> , 2019 , 55, 168-169	0.7	

- 3 Circulating tumor DNA analysis (ctDNA) for genomic testing in NSCLC patients with isolated CNS progression.. *Journal of Clinical Oncology*, **2019**, 37, 2015-2015 2.2
- 2 Efficacy of tyrosine kinase inhibitors (TKIs) based on the ALK resistance mutations on amplicon-based liquid biopsy in ALK positive non-small cell lung cancer (NSCLC) patients (pts).. *Journal of Clinical Oncology*, **2019**, 37, 3055-3055 2.2
- 1 Prediction of the molecular status in non-small cell lung cancer based on metastatic pattern: A free webtool powered by artificial intelligence.. *Journal of Clinical Oncology*, **2020**, 38, 9535-9535 2.2